Author Archives: Warren Woessner

Chromadex v. Elysium Health – It’s Only Natural!

Posted on February 24, 2023 by Warren Woessner

On February 13, 2023, a Fed. Cir. panel of Judges Prost, Chen and Stoll (Prost writing) held, in Appeal no. 2022-1116, that the asserted claims 1-3 of U.S. Patent No. 8,197, 807 are directed to unpatentable subject matter, namely to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

“Inequitable Conduct: Refresher and Update” Panel on March 16

Posted on February 23, 2023 by Warren Woessner

I will be on a panel,  “Inequitable Conduct: Refresher and Update,” with Danny Huntington of Rothwell Figg and William Covey of the PTO OED. The panel will take place on Thursday, March 16 at the 2023 IPOwners Spring SummitTM in … Continue reading →

Posted in Inequitable Conduct/Rule 56, Uncategorized | Tagged , , , | Leave a comment

PTO Expands the Scope of the Immunotherapy Pilot Program

Posted on December 21, 2022 by Warren Woessner

The PTO’s Cancer Immunotherapy Pilot Project, begun in 2016, has been deemed a success. It permitted an applicant claiming a method to treat cancer using immunotherapy to file a petition to accelerate issuance of the first Examination Report. When the … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

Moderna to Pfizer: “The Pandemic is Over”

Posted on September 6, 2022 by Warren Woessner

On August 26th, Modernatx, Inc. and Moderna US, Inc. sued Pfizer and Biontech SE,  (Case 1:22-cv-11378 [D. Mass.]) for treble damages and attorney’s fees related to the alleged direct or indirect infringement of three of Moderna’s patents with claims directed … Continue reading →

Posted in Litigation Issues | Tagged , , | Leave a comment